<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="anthelminthic/PMC6826424/results/search/disease/results.xml">
  <result pre="indicated that HMGA2 was mainly overexpressed in gastrointestinal cancers including" exact="colorectal cancer." post="Intriguingly, HMGA2 overexpression had no prognostic impacts on cancer"/>
  <result pre="colorectal cancer. Intriguingly, HMGA2 overexpression had no prognostic impacts on" exact="cancer" post="patients’ overall and disease-free survivals. In addition, HMGA2-overexpressing colorectal"/>
  <result pre="on cancer patients’ overall and disease-free survivals. In addition, HMGA2-overexpressing" exact="colorectal cancer" post="cell lines did not display higher susceptibility to a"/>
  <result pre="cancer patients’ overall and disease-free survivals. In addition, HMGA2-overexpressing colorectal" exact="cancer" post="cell lines did not display higher susceptibility to a"/>
  <result pre="protein A4 (S100A4) may be a druggable vulnerability for HMGA2-overexpressing" exact="colorectal cancer." post="A repurposing S100A4 inhibitor, niclosamide, was found to reverse"/>
  <result pre="was found to reverse the HMGA2-driven gene signature both in" exact="colorectal cancer" post="cell lines and patients’ tissues. In vitro and in"/>
  <result pre="found to reverse the HMGA2-driven gene signature both in colorectal" exact="cancer" post="cell lines and patients’ tissues. In vitro and in"/>
  <result pre="tissues. In vitro and in vivo experiments validated that HMGA2-overexpressing" exact="colorectal cancer" post="cells were more sensitive to niclosamide. However, inhibition of"/>
  <result pre="In vitro and in vivo experiments validated that HMGA2-overexpressing colorectal" exact="cancer" post="cells were more sensitive to niclosamide. However, inhibition of"/>
  <result pre="identified that niclosamide inhibited more cell-cycle-related gene expression in HMGA2-overexpressing" exact="colorectal cancer" post="cells, which may explain its selective anticancer effect. Together,"/>
  <result pre="that niclosamide inhibited more cell-cycle-related gene expression in HMGA2-overexpressing colorectal" exact="cancer" post="cells, which may explain its selective anticancer effect. Together,"/>
  <result pre="our study repurposes an anthelminthic drug niclosamide for treating HMGA2-overexpression" exact="colorectal cancer." post="bioinformatics Connectivity Map colorectal cancer drug repurposing HMGA2 S100A4"/>
  <result pre="drug niclosamide for treating HMGA2-overexpression colorectal cancer. bioinformatics Connectivity Map" exact="colorectal cancer" post="drug repurposing HMGA2 S100A4 1. Introduction High mobility group"/>
  <result pre="niclosamide for treating HMGA2-overexpression colorectal cancer. bioinformatics Connectivity Map colorectal" exact="cancer" post="drug repurposing HMGA2 S100A4 1. Introduction High mobility group"/>
  <result pre="shown to elicit anticancer activity against adenomatous polyposis coli (APC)-mutated" exact="colorectal cancer" post="through downregulating the Wnt signaling pathway [17]. In addition,"/>
  <result pre="to elicit anticancer activity against adenomatous polyposis coli (APC)-mutated colorectal" exact="cancer" post="through downregulating the Wnt signaling pathway [17]. In addition,"/>
  <result pre="is not a suitable prognostic biomarker and therapeutic target in" exact="colorectal cancer." post="However, HMGA2 overexpression in colorectal cancer cells leads to"/>
  <result pre="and therapeutic target in colorectal cancer. However, HMGA2 overexpression in" exact="colorectal cancer" post="cells leads to an increased sensitivity to an anthelminthic"/>
  <result pre="therapeutic target in colorectal cancer. However, HMGA2 overexpression in colorectal" exact="cancer" post="cells leads to an increased sensitivity to an anthelminthic"/>
  <result pre="niclosamide. Our study provides a novel therapeutic strategy for HMGA2-overexpressing" exact="colorectal cancer." post="2. Results 2.1. Pan-Cancer Analyses of HMGA2 Gene Expression"/>
  <result pre="dataset consists of the gene expression profiles from 917 human" exact="cancer" post="cell line spanning 36 cancer types [26]. High expression"/>
  <result pre="expression profiles from 917 human cancer cell line spanning 36" exact="cancer" post="types [26]. High expression of HMGA2 mRNA is found"/>
  <result pre="squamous cell carcinoma (HNSC), lung squamous cell carcinoma (LUSC), ovarian" exact="serous cystadenocarcinoma" post="(OV), rectum adenocarcinoma (READ), skin cutaneous melanoma (SKCM), stomach"/>
  <result pre="was a potential therapeutic target, we established a HMGA2-overexpressing DLD-1" exact="colorectal cancer" post="cell line. The overexpression of HMGA2 mRNA and protein"/>
  <result pre="a potential therapeutic target, we established a HMGA2-overexpressing DLD-1 colorectal" exact="cancer" post="cell line. The overexpression of HMGA2 mRNA and protein"/>
  <result pre="DNA [27,28]. To investigate whether netropsin can selectively kill HMGA2-overexpressing" exact="cancer" post="cells, both DLD-1-Vector and DLD-1-HMGA2 cells were treated with"/>
  <result pre="3D). To further confirm that the effect of netropsin on" exact="colorectal cancer" post="cell viability was not affected by HMGA2 expression, HCT116"/>
  <result pre="To further confirm that the effect of netropsin on colorectal" exact="cancer" post="cell viability was not affected by HMGA2 expression, HCT116"/>
  <result pre="may not a suitable prognosis biomarker and therapeutic target for" exact="colorectal cancer." post="2.3. S100A4 Is a Potential Surrogate Therapeutic Target for"/>
  <result pre="for HMGA2-Overexpressing Colorectal Cancer To identify druggable vulnerability of HGMA2-overexpressing" exact="colorectal cancer," post="microarray analysis was performed and found that 396 gene"/>
  <result pre="tissues. In addition, higher S100A4 expression was observed in various" exact="cancer" post="types compared to MYLK, BDNF, and PCOLCE2 (Figure S2)."/>
  <result pre="PCOLCE2 (Figure S2). S100A4 is a well-known metastasis-inducing gene in" exact="colorectal cancer" post="and S100A4 inhibition for therapeutic intervention is suggested [32,33]."/>
  <result pre="(Figure S2). S100A4 is a well-known metastasis-inducing gene in colorectal" exact="cancer" post="and S100A4 inhibition for therapeutic intervention is suggested [32,33]."/>
  <result pre="a gene related to angiogenesis, but not EMT, in the" exact="cancer" post="hallmark collection of Molecular Signatures Database (MSigDB) [31], it"/>
  <result pre="S100A4 might serve as a potential therapeutic target for HMGA2-overexpressing" exact="colorectal cancer." post="To confirm the S100A4 mRNA was upregulated in HMGA2-overexpressing"/>
  <result pre="prognostic impact of S100A4 on overall and disease-free survivals in" exact="colorectal cancer," post="Kaplan–Meier survival analysis was performed. Although S100A4 expression could"/>
  <result pre="performed. Although S100A4 expression could not predict the overall survival," exact="colorectal cancer" post="patients with high S100A4 expression displayed poor disease-free survival"/>
  <result pre="Although S100A4 expression could not predict the overall survival, colorectal" exact="cancer" post="patients with high S100A4 expression displayed poor disease-free survival"/>
  <result pre="might serve as a suitable molecular target for treating HMGA2-overexpressing" exact="colorectal cancer." post="2.4. Connectivity Map (CMap) Analysis Identified that S100A4 Inhibition"/>
  <result pre="a web-based database consisting of gene expression signatures from human" exact="cancer" post="cell lines treated with small molecules or transfected with"/>
  <result pre="employed CMap analysis to investigate the genetic dependency of HMGA2-overexpressing" exact="colorectal cancer." post="The differentially expressed genes (DEGs) with absolute Log2 fold"/>
  <result pre="further supporting the potency of niclosamide to inhibit S100A4 in" exact="colorectal cancer." post="In addition, we queried the CMap database with the"/>
  <result pre="S100A4 inhibition by niclosamide may exhibit therapeutic benefit for HMGA2-overexpressing" exact="colorectal cancer." post="2.5. Connectivity Map (CMap) Analysis Identified that S100A4 Inhibition"/>
  <result pre="signature provides clinical benefits, the gene expression profile of a" exact="colorectal cancer" post="patient cohort (GSE32323 [46]) was obtained from the GEO"/>
  <result pre="provides clinical benefits, the gene expression profile of a colorectal" exact="cancer" post="patient cohort (GSE32323 [46]) was obtained from the GEO"/>
  <result pre="Figure 6 (the lower part), the HMGA2-driven gene signature in" exact="colorectal cancer" post="patients was reversed by S100A4-knockdown (summary score = −96.55)"/>
  <result pre="6 (the lower part), the HMGA2-driven gene signature in colorectal" exact="cancer" post="patients was reversed by S100A4-knockdown (summary score = −96.55)"/>
  <result pre="demonstrate the in vivo anticancer activity of niclosamide against HMGA2-overexpressing" exact="colorectal cancer," post="DLD-1-Vector and DLD-1-HMGA2 cells were transplanted simultaneously into the"/>
  <result pre="selective in vitro and in vivo anticancer activity against HMGA2-overexpressing" exact="colorectal cancer." post="2.7. Inhibition of S100A4 Is Not Sufficient to Selectively"/>
  <result pre="CMap drugs of 10 μM are usually used to treat" exact="cancer" post="cells and generate gene expression signatures, therefore the inability"/>
  <result pre="examined whether Wnt/β-catenin inhibitors could exhibit selective cytotoxicity against HMGA2-overexpressing" exact="colorectal cancer" post="cells. As shown in Figure 8C, a Wnt/β-catenin inhibitor,"/>
  <result pre="whether Wnt/β-catenin inhibitors could exhibit selective cytotoxicity against HMGA2-overexpressing colorectal" exact="cancer" post="cells. As shown in Figure 8C, a Wnt/β-catenin inhibitor,"/>
  <result pre="indicate that niclosamide is a better therapeutic drug for HMGA2-overexpressing" exact="colorectal cancer" post="than other Wnt/β-catenin pathway inhibitors. In addition, inhibition of"/>
  <result pre="that niclosamide is a better therapeutic drug for HMGA2-overexpressing colorectal" exact="cancer" post="than other Wnt/β-catenin pathway inhibitors. In addition, inhibition of"/>
  <result pre="that S100A4 downregulation was not sufficient to selectively kill HMGA2-overexpressing" exact="colorectal cancer" post="cells. In addition, S100A4 knockdown did not further enhance"/>
  <result pre="S100A4 downregulation was not sufficient to selectively kill HMGA2-overexpressing colorectal" exact="cancer" post="cells. In addition, S100A4 knockdown did not further enhance"/>
  <result pre="the differential effect of niclosamide in HMGA2-low and HMGA2-high expressing" exact="colorectal cancer" post="cells, RNA sequencing for niclosamide-treated DLD-1-Vector and DLD-1-HMGA2 cells"/>
  <result pre="differential effect of niclosamide in HMGA2-low and HMGA2-high expressing colorectal" exact="cancer" post="cells, RNA sequencing for niclosamide-treated DLD-1-Vector and DLD-1-HMGA2 cells"/>
  <result pre="and cell cycle) and DNA repair (homologous recombination and Fanconi" exact="anemia" post="pathway). As a representative, the cell cycle pathway (hsa04114)"/>
  <result pre="with cell cycle progression and DNA repair pathways in HMGA2-overexpressing" exact="colorectal cancer," post="which may account for its higher cytotoxicity. 3. Discussion"/>
  <result pre="because negative prognostic impacts of HMGA2 overexpression in the above" exact="cancer" post="types have been reported previously [54,55,56,57,58,59]. We hypothesized that"/>
  <result pre="that such discrepancy may be resulted from the source of" exact="cancer" post="patients’ data, which can be supported by a recent"/>
  <result pre="be supported by a recent meta-analysis based on literatures (15" exact="cancer" post="types) and TCGA datasets (33 cancer types) [60]. They"/>
  <result pre="based on literatures (15 cancer types) and TCGA datasets (33" exact="cancer" post="types) [60]. They found that high HMGA2 expression is"/>
  <result pre="expression is associated with shorter overall and disease-free survivals in" exact="cancer" post="patients. However, consistent results are only observed in six"/>
  <result pre="cancer patients. However, consistent results are only observed in six" exact="cancer" post="types. For clear cell renal cell carcinoma, head and"/>
  <result pre="are only observed in six cancer types. For clear cell" exact="renal cell carcinoma," post="head and neck cancer, hepatocellular carcinoma, and pancreatic ductal"/>
  <result pre="in six cancer types. For clear cell renal cell carcinoma," exact="head and neck cancer," post="hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, patients with high"/>
  <result pre="For clear cell renal cell carcinoma, head and neck cancer," exact="hepatocellular carcinoma," post="and pancreatic ductal adenocarcinoma, patients with high HMGA2 expression"/>
  <result pre="this study was to identify therapeutic agents selectively targeting HMGA2-overexpressing" exact="colorectal cancer." post="HMGA2 has been considered a therapeutic target in colorectal"/>
  <result pre="colorectal cancer. HMGA2 has been considered a therapeutic target in" exact="colorectal cancer." post="For example, HMGA2 silencing by small interfering (si)RNA, shRNA"/>
  <result pre="shown to inhibit cell growth and induce apoptosis in human" exact="colorectal cancer" post="cells [61,62,63,64]. However, such observations imply that HMGA2 inhibition-based"/>
  <result pre="to inhibit cell growth and induce apoptosis in human colorectal" exact="cancer" post="cells [61,62,63,64]. However, such observations imply that HMGA2 inhibition-based"/>
  <result pre="able to reduce HMGA2 expression and suppress HMGA-mediated EMT in" exact="colorectal cancer" post="cells. Thus, NVP-AUY922 can be viewed as an HMGA2"/>
  <result pre="to reduce HMGA2 expression and suppress HMGA-mediated EMT in colorectal" exact="cancer" post="cells. Thus, NVP-AUY922 can be viewed as an HMGA2"/>
  <result pre="However, knockdown of HMGA2 by siRNA increases the sensitivity of" exact="colorectal cancer" post="cells to NVP-AUY922, whereas HMGA2 overexpression attenuates the anticancer"/>
  <result pre="knockdown of HMGA2 by siRNA increases the sensitivity of colorectal" exact="cancer" post="cells to NVP-AUY922, whereas HMGA2 overexpression attenuates the anticancer"/>
  <result pre="inhibitors is limited by the endogenous expression of HMGA2 in" exact="colorectal cancer" post="cells. Drug repurposing is a promising strategy for the"/>
  <result pre="is limited by the endogenous expression of HMGA2 in colorectal" exact="cancer" post="cells. Drug repurposing is a promising strategy for the"/>
  <result pre="to fight against cancers. There are increasing repurposed drugs for" exact="colorectal cancer," post="including niclosamide [66]. Currently, few clinical trials of niclosamide"/>
  <result pre="niclosamide plus standard-dose enzalutamide (a nonsteroidal antiandrogen) in metastatic castration-resistant" exact="prostate cancer" post="[67]. However, the result is disappointing. The plasma concentration"/>
  <result pre="plus standard-dose enzalutamide (a nonsteroidal antiandrogen) in metastatic castration-resistant prostate" exact="cancer" post="[67]. However, the result is disappointing. The plasma concentration"/>
  <result pre="of niclosamide does not pass the threshold shown to inhibit" exact="prostate cancer" post="growth [67]. The finding that niclosamide inhibits S100A4-driven metastasis"/>
  <result pre="niclosamide does not pass the threshold shown to inhibit prostate" exact="cancer" post="growth [67]. The finding that niclosamide inhibits S100A4-driven metastasis"/>
  <result pre="number: NCT02519582) to evaluate its safety and efficacy in metastatic" exact="colorectal cancer" post="[18,19]. This trial is expected to be completed by"/>
  <result pre="NCT02519582) to evaluate its safety and efficacy in metastatic colorectal" exact="cancer" post="[18,19]. This trial is expected to be completed by"/>
  <result pre="to demonstrate the feasibility of oral niclosamide for treating metastatic" exact="colorectal cancer." post="It has been reported that niclosamide-mediated S100A4 downregulation contributes"/>
  <result pre="involve in the selective anticancer effect of niclosamide against HMGA2-overexpressing" exact="colorectal cancer" post="cells. One limitation of this study is few biological"/>
  <result pre="in the selective anticancer effect of niclosamide against HMGA2-overexpressing colorectal" exact="cancer" post="cells. One limitation of this study is few biological"/>
  <result pre="USA). 4.6. Cell Culture and Transfection DLD-1 and HCT116 human" exact="colorectal cancer" post="cells were cultured in RPMI-1640 medium supplemented with 10%"/>
  <result pre="4.6. Cell Culture and Transfection DLD-1 and HCT116 human colorectal" exact="cancer" post="cells were cultured in RPMI-1640 medium supplemented with 10%"/>
  <result pre="HMGA2 to S100A4 that predicts a poor disease-free survival in" exact="colorectal cancer" post="patients. In addition, niclosamide (a S100A4 inhibitor) exhibits more"/>
  <result pre="to S100A4 that predicts a poor disease-free survival in colorectal" exact="cancer" post="patients. In addition, niclosamide (a S100A4 inhibitor) exhibits more"/>
  <result pre="cannot fully explain the sensitizing effect of niclosamide on HMGA2-overexpressing" exact="colorectal cancer" post="cells, suggesting that additional mechanisms are involved. The results"/>
  <result pre="fully explain the sensitizing effect of niclosamide on HMGA2-overexpressing colorectal" exact="cancer" post="cells, suggesting that additional mechanisms are involved. The results"/>
  <result pre="cells. Nevertheless, our study provides a basis for treating HMGA2-overexpressing" exact="colorectal cancer" post="by niclosamide, and the exact mechanism of action warrants"/>
  <result pre="Nevertheless, our study provides a basis for treating HMGA2-overexpressing colorectal" exact="cancer" post="by niclosamide, and the exact mechanism of action warrants"/>
  <result pre="of HMGA2, MYLK, BDNK, PCOLCE2, and S100A4 in normal and" exact="cancer" post="tissues, Figure S3: Connectivity mapping for the gene signature"/>
  <result pre="Connectivity Map (CMap) analysis, Table S3: The HMGA2-correlated genes in" exact="colorectal cancer" post="patients, Table S4: RNA sequencing for niclosamide-treated DLD-1-Vector cells,"/>
  <result pre="Map (CMap) analysis, Table S3: The HMGA2-correlated genes in colorectal" exact="cancer" post="patients, Table S4: RNA sequencing for niclosamide-treated DLD-1-Vector cells,"/>
  <result pre="cancerMol. Cancer Res.2008674375010.1158/1541-7786.MCR-07-009518505920 7.MalekA.BakhidzeE.NoskeA.SersC.AignerA.SchaferR.TchernitsaO.HMGA2 gene is a promising target for" exact="ovarian cancer" post="silencing therapyInt. J. Cancer200812334835610.1002/ijc.2349118452175 8.MorishitaA.ZaidiM.R.MitoroA.SankarasharmaD.SzabolcsM.OkadaY.D’ArmientoJ.ChadaK.HMGA2 is a driver of"/>
  <result pre="Cancer Res.2008674375010.1158/1541-7786.MCR-07-009518505920 7.MalekA.BakhidzeE.NoskeA.SersC.AignerA.SchaferR.TchernitsaO.HMGA2 gene is a promising target for ovarian" exact="cancer" post="silencing therapyInt. J. Cancer200812334835610.1002/ijc.2349118452175 8.MorishitaA.ZaidiM.R.MitoroA.SankarasharmaD.SzabolcsM.OkadaY.D’ArmientoJ.ChadaK.HMGA2 is a driver of"/>
  <result pre="11.MotoyamaK.InoueH.NakamuraY.UetakeH.SugiharaK.MoriM.Clinical significance of high mobility group A2 in human gastric" exact="cancer" post="and its relationship to let-7 microRNA familyClin. Cancer Res.2008142334234010.1158/1078-0432.CCR-07-466718413822"/>
  <result pre="action of reagents that uncouple oxidative phosphorylationNature19692211016101810.1038/2211016a04180173 15.LiY.LiP.K.RobertsM.J.ArendR.C.SamantR.S.BuchsbaumD.J.Multi-targeted therapy of" exact="cancer" post="by niclosamide: A new application for an old drugCancer"/>
  <result pre="niclosamide in patients with metachronous or sychronous metastases of a" exact="colorectal cancer" post="progressing after therapy: The NIKOLO trialBMC Cancer201818e29710.1186/s12885-018-4197-9 20.WuC.JinX.TsuengG.AfrasiabiC.SuA.I.BioGPS: Building"/>
  <result pre="in patients with metachronous or sychronous metastases of a colorectal" exact="cancer" post="progressing after therapy: The NIKOLO trialBMC Cancer201818e29710.1186/s12885-018-4197-9 20.WuC.JinX.TsuengG.AfrasiabiC.SuA.I.BioGPS: Building"/>
  <result pre="and interactive analysisNucleic Acids Res.20194755656010.1093/nar/gkz43031114875 24.TangZ.LiC.KangB.GaoG.LiC.ZhangZ.GEPIA: A web server for" exact="cancer" post="and normal gene expression profiling and interactive analysesNucleic Acids"/>
  <result pre="and human protein-encoding transcriptomesProc. Natl. Acad. Sci. USA20041016062606710.1073/pnas.040078210115075390 26.BarretinaJ.CaponigroG.StranskyN.VenkatesanK.MargolinA.A.KimS.WilsonC.J.LeharJ.KryukovG.V.SonkinD.et al.The" exact="cancer" post="cell line encyclopedia enables predictive modelling of anticancer drug"/>
  <result pre="signatures database (MSigDB) hallmark gene set collectionCell Syst.2015141742510.1016/j.cels.2015.12.00426771021 32.DahlmannM.KobeltD.WaltherW.MudduluruG.SteinU.S100A4 in" exact="cancer" post="metastasis: Wnt signaling-driven interventions for metastasis restrictionCancers (Basel)20168e5910.3390/cancers806005927331819 33.WeidleU.H.BirzeleF.KrugerA.Molecular"/>
  <result pre="in liver metastasis of colorectal cancerClin. Exp. Metastasis20153262363510.1007/s10585-015-9732-326104118 34.FeiF.QuJ.ZhangM.LiY.ZhangS.S100A4 in" exact="cancer" post="progression and metastasis: A systematic reviewOncotarget20178732197323910.18632/oncotarget.1801629069865 35.LambJ.The connectivity map:"/>
  <result pre="1,000,000 profilesCell201717114371452e141710.1016/j.cell.2017.10.04929195078 38.LiuL.QiL.KnifleyT.PiecoroD.W.RychahouP.LiuJ.MitovM.I.MartinJ.WangC.WuJ.et al.S100A4 alters metabolism and promotes invasion of" exact="lung cancer" post="cells by up-regulating mitochondrial complex I protein NDUFS2J. Biol."/>
  <result pre="profilesCell201717114371452e141710.1016/j.cell.2017.10.04929195078 38.LiuL.QiL.KnifleyT.PiecoroD.W.RychahouP.LiuJ.MitovM.I.MartinJ.WangC.WuJ.et al.S100A4 alters metabolism and promotes invasion of lung" exact="cancer" post="cells by up-regulating mitochondrial complex I protein NDUFS2J. Biol."/>
  <result pre="metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in" exact="colon cancer" post="cellsMol. Biol. Cell2011223344335410.1091/mbc.e10-09-073921795396 42.SteinU.ArltF.SmithJ.SackU.HerrmannP.WaltherW.LemmM.FichtnerI.ShoemakerR.H.SchlagP.M.Intervening in beta-catenin signaling by sulindac"/>
  <result pre="is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon" exact="cancer" post="cellsMol. Biol. Cell2011223344335410.1091/mbc.e10-09-073921795396 42.SteinU.ArltF.SmithJ.SackU.HerrmannP.WaltherW.LemmM.FichtnerI.ShoemakerR.H.SchlagP.M.Intervening in beta-catenin signaling by sulindac"/>
  <result pre="Biol. Cell2011223344335410.1091/mbc.e10-09-073921795396 42.SteinU.ArltF.SmithJ.SackU.HerrmannP.WaltherW.LemmM.FichtnerI.ShoemakerR.H.SchlagP.M.Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent" exact="colon cancer" post="metastasisNeoplasia20111313114410.1593/neo.10117221403839 43.GarrettS.C.HodgsonL.RybinA.ToutchkineA.HahnK.M.LawrenceD.S.BresnickA.R.A biosensor of S100A4 metastasis factor activation: Inhibitor"/>
  <result pre="Cell2011223344335410.1091/mbc.e10-09-073921795396 42.SteinU.ArltF.SmithJ.SackU.HerrmannP.WaltherW.LemmM.FichtnerI.ShoemakerR.H.SchlagP.M.Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon" exact="cancer" post="metastasisNeoplasia20111313114410.1593/neo.10117221403839 43.GarrettS.C.HodgsonL.RybinA.ToutchkineA.HahnK.M.LawrenceD.S.BresnickA.R.A biosensor of S100A4 metastasis factor activation: Inhibitor"/>
  <result pre="S100A4 and myosin-IIABiochemistry (Mosc.)2011507218722710.1021/bi200853y21749055 46.KhamasA.IshikawaT.ShimokawaK.MogushiK.IidaS.IshiguroM.MizushimaH.TanakaH.UetakeH.SugiharaK.Screening for epigenetically masked genes in" exact="colorectal cancer" post="Using 5-Aza-2’-deoxycytidine, microarray and gene expression profileCancer Genom. Proteom.201296775"/>
  <result pre="and myosin-IIABiochemistry (Mosc.)2011507218722710.1021/bi200853y21749055 46.KhamasA.IshikawaT.ShimokawaK.MogushiK.IidaS.IshiguroM.MizushimaH.TanakaH.UetakeH.SugiharaK.Screening for epigenetically masked genes in colorectal" exact="cancer" post="Using 5-Aza-2’-deoxycytidine, microarray and gene expression profileCancer Genom. Proteom.201296775"/>
  <result pre="55.NieD.ZhangL.GuoQ.MaoX.High mobility group protein A2 overexpression indicates poor prognosis for" exact="cancer" post="patients: A meta-analysisOncotarget201891237124710.18632/oncotarget.2308529416690 56.PallanteP.SepeR.PucaF.FuscoA.High mobility group a proteins as"/>
  <result pre="human colorectal carcinomaJ. Gastrointest. Cancer20174815616310.1007/s12029-016-9871-z27629422 62.XuX.WangY.DengH.LiuC.WuJ.LaiM.HMGA2 enhances 5-fluorouracil chemoresistance in" exact="colorectal cancer" post="via the Dvl2/Wnt pathwayOncotarget201899963997410.18632/oncotarget.2413329515783 63.WuH.LiangY.ShenL.ShenL.MicroRNA-204 modulates colorectal cancer cell"/>
  <result pre="colorectal carcinomaJ. Gastrointest. Cancer20174815616310.1007/s12029-016-9871-z27629422 62.XuX.WangY.DengH.LiuC.WuJ.LaiM.HMGA2 enhances 5-fluorouracil chemoresistance in colorectal" exact="cancer" post="via the Dvl2/Wnt pathwayOncotarget201899963997410.18632/oncotarget.2413329515783 63.WuH.LiangY.ShenL.ShenL.MicroRNA-204 modulates colorectal cancer cell"/>
  <result pre="chemoresistance in colorectal cancer via the Dvl2/Wnt pathwayOncotarget201899963997410.18632/oncotarget.2413329515783 63.WuH.LiangY.ShenL.ShenL.MicroRNA-204 modulates" exact="colorectal cancer" post="cell sensitivity in response to 5-fluorouracil-based treatment by targeting"/>
  <result pre="in colorectal cancer via the Dvl2/Wnt pathwayOncotarget201899963997410.18632/oncotarget.2413329515783 63.WuH.LiangY.ShenL.ShenL.MicroRNA-204 modulates colorectal" exact="cancer" post="cell sensitivity in response to 5-fluorouracil-based treatment by targeting"/>
  <result pre="mobility group protein A2Biol. Open2016556357010.1242/bio.01500827095441 64.YuF.Y.TuY.DengY.GuoC.NingJ.ZhuY.LvX.YeH.MiR-4500 is epigenetically downregulated in" exact="colorectal cancer" post="and functions as a novel tumor suppressor by regulating"/>
  <result pre="group protein A2Biol. Open2016556357010.1242/bio.01500827095441 64.YuF.Y.TuY.DengY.GuoC.NingJ.ZhuY.LvX.YeH.MiR-4500 is epigenetically downregulated in colorectal" exact="cancer" post="and functions as a novel tumor suppressor by regulating"/>
  <result pre="in the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of" exact="colorectal cancer" post="cellsPeerJ20164e168310.7717/peerj.168326893968 66.FongW.ToK.K.W.Drug repurposing to overcome resistance to various therapies"/>
  <result pre="the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of colorectal" exact="cancer" post="cellsPeerJ20164e168310.7717/peerj.168326893968 66.FongW.ToK.K.W.Drug repurposing to overcome resistance to various therapies"/>
  <result pre="prognostic impact of HMGA2 on overall and disease-free survival of" exact="cancer" post="patients. The Kaplan–Meier survival plots for cancer patients with"/>
  <result pre="disease-free survival of cancer patients. The Kaplan–Meier survival plots for" exact="cancer" post="patients with high and low HMGA2 expression were generated"/>
  <result pre="database. TPM, transcript per million. Figure 3 Characterization of HMGA2-overexpressing" exact="colorectal cancer" post="cells. (A) The mRNA and protein expressions of HMGA2"/>
  <result pre="TPM, transcript per million. Figure 3 Characterization of HMGA2-overexpressing colorectal" exact="cancer" post="cells. (A) The mRNA and protein expressions of HMGA2"/>
  <result pre="4 Upregulation of S100 calcium-binding protein A4 (S100A4) in HMGA2-overexpression" exact="colorectal cancer" post="cells. (A) The differentially expressed genes (DEGs) in DLD-1-HMGA2"/>
  <result pre="Upregulation of S100 calcium-binding protein A4 (S100A4) in HMGA2-overexpression colorectal" exact="cancer" post="cells. (A) The differentially expressed genes (DEGs) in DLD-1-HMGA2"/>
  <result pre="enzyme-linked immunosorbent assay (ELISA); (D) the Kaplan–Meier survival plots for" exact="colorectal cancer" post="patients with high and low S100A4 expression were generated"/>
  <result pre="immunosorbent assay (ELISA); (D) the Kaplan–Meier survival plots for colorectal" exact="cancer" post="patients with high and low S100A4 expression were generated"/>
  <result pre="clinical implication of S100 calcium-binding protein A4 (S100A4)-targeting niclosamide for" exact="colorectal cancer." post="The upper part: The most similar and dissimilar genes"/>
  <result pre="map. The lower part: Connections of HMGA2-driven gene signature in" exact="colorectal cancer" post="patients with the HMGA2/S100A4 knockdown and niclosamide were analyzed"/>
  <result pre="The lower part: Connections of HMGA2-driven gene signature in colorectal" exact="cancer" post="patients with the HMGA2/S100A4 knockdown and niclosamide were analyzed"/>
  <result pre="score. Figure 7 Effect of niclosamide on S100A4 expression and" exact="cancer" post="growth in HMGA2-overexpressing colorectal cancer cells. (A) DLD-1-Vector and"/>
  <result pre="of niclosamide on S100A4 expression and cancer growth in HMGA2-overexpressing" exact="colorectal cancer" post="cells. (A) DLD-1-Vector and DLD-1-HMGA2 cells were treated with"/>
  <result pre="niclosamide on S100A4 expression and cancer growth in HMGA2-overexpressing colorectal" exact="cancer" post="cells. (A) DLD-1-Vector and DLD-1-HMGA2 cells were treated with"/>
  <result pre="8 Effect of S100A4 inhibition on cell viability in HMGA2-overexpressing" exact="colorectal cancer" post="cells. (A) DLD-1-Vector and DLD-1-HMGA2 cells were treated with"/>
  <result pre="Effect of S100A4 inhibition on cell viability in HMGA2-overexpressing colorectal" exact="cancer" post="cells. (A) DLD-1-Vector and DLD-1-HMGA2 cells were treated with"/>
  <result pre="polysaccharide biosynthesis domain containing 1 −4.72 NPNT nephronectin −4.57 CFTR" exact="cystic fibrosis" post="transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)"/>
  <result pre="NPTX2 neuronal pentraxin II −4.03 KIT v-kit Hardy-Zuckerman 4 feline" exact="sarcoma" post="viral oncogene homolog −3.99 SH3BGRL SH3 domain binding glutamic"/>
 </snippets>
</snippetsTree>
